Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
CNVS vs BBLG: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CNVS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)
CNVS Overall Winner
6-Pillar Tally: CNVS 5 – 1 BBLG
Matrix Metrics: CNVS 6 – 4 BBLG
As of Nov 20, 2026, Cineverse Corp. (CNVS) is the stronger overall head-to-head candidate over Bone Biologics Corp (BBLG) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). CNVS carries a Unified Composite Score of 35.9/100 (SELL) at $1.73 (38.8x Forward P/E, -12.0% operating margin), whereas BBLG carries 44.8/100 (HOLD) at $0.27 (N/M Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While BBLG currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. CNVS 35.9/100 SELL), CNVS captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-12.0% vs. 0.0% operating margin) and revenue trajectory (+110.0% vs. +0.0% YoY).
- Technical & Structure Timing Caution: CNVS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.9); meanwhile BBLG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CNVS vs BBLG
CNVS
Head-to-Head Winner
Cineverse Corp. Class A Common Stock
$1.73
-5.46% 1D
Market Cap
$49.1M
TTM Revenue
$99M
Forward P/E
38.8x
Beta / 30D Vol
1.19β · 110% Vol
Unified Composite Score
35.9
SELL
Tech 15.0
Fund 36.0
Flow 54.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
BBLG
Bone Biologics Corp Common Stock
$0.27
-2.4% 1D
Market Cap
$932,329
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
0.97β · 102% Vol
Unified Composite Score
44.8
HOLD
Tech 33.0
Fund 48.0
Flow 50.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (CNVS 5 – 1 BBLG)
1. Valuation Multiples
CNVS
Forward P/E
38.8x
N/M
Trailing P/E
38.8x
N/M
PEG Ratio
0.46x
N/M
EV / Revenue
0.7x
N/M
2. Growth & Scale
CNVS
Revenue Growth (YoY)
+110.0%
+0.0%
Earnings Growth (YoY)
+21.1%
+0.0%
TTM Revenue (USD)
$99M
N/A
Market Cap
$49.1M
$932,329
3. Profitability & Quality
BBLG
Gross Margin
42.7%
N/A
Operating Margin
-12.0%
0.0%
Net Profit Margin
-2.1%
0.0%
Return on Equity (ROE)
-4.6%
-47.5%
4. Balance Sheet & Cash Flow
CNVS
Cash Generation (TTM)
-$18M
N/A
Cash Flow Margin
-17.9%
N/A
Net Cash / Leverage
$22M Net Debt (0.65x D/E)
$1.76 Book/Sh · -47.5% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
CNVS
Options Structure Phase
UNCLASSIFIED
BREAKDOWN
Current IV / %ile
131.8% (28th %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat
CNVS
OpEx & R&D Intensity
54.7% of Rev ($54M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Entertainment Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CNVS (6) vs BBLG (4)| Institutional Metric | CNVS | BBLG | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $49.1M | $932,329 | CNVS | |
| Trailing P/E Ratio | 38.8x | N/M | CNVS | |
| Forward P/E Ratio | 38.8x | N/M | CNVS | |
| Revenue Growth (YoY) | +110.0% | +0.0% | CNVS | |
| Operating Margin (TTM) | -12.0% | 0.0% | BBLG | |
| Net Profit Margin | -2.1% | 0.0% | BBLG | |
| Return on Equity (ROE) | -4.6% | -47.5% | CNVS | |
| 52-Week Range Position | 16% ($1–$3) | 0% ($0–$2) | CNVS | |
| Beta / 30D Volatility | 1.19β · 110% Vol | 0.97β · 102% Vol | BBLG | |
| Unified Institutional Score | 35.9 / 100 (SELL) | 44.8 / 100 (HOLD) | BBLG | |
| Trailing 12M Revenue (USD) | $99M | N/A | Scale | |
| Gross Profit Margin (TTM) | 42.7% | N/A | Quality | |
| PEG Ratio & EV / Revenue | 0.46x PEG · 0.7x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$18M ($22M Net Debt (0.65x D/E)) | N/A ($1.76 Book/Sh · -47.5% ROE) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CNVS +46.14 pp
3M Horizon
CNVS +23.92 pp
6M Horizon
CNVS +48.6 pp
1Y Horizon
CNVS +50.48 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CNVS Revenue | BBLG Revenue | CNVS Op. Margin | BBLG Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $50M | $1.07B | -10.5% | -0.2% | BBLG |
| FY2020 | $0M | $1.07B | -310.6% | -0.1% | BBLG |
| FY2021 | $0M | N/A | -2245.5% | N/A | CNVS |
| FY2022 | $60M | N/A | -1.7% | N/A | CNVS |
| FY2023 | $70M | N/A | -13.1% | N/A | CNVS |
| FY2024 | $50M | N/A | -32.0% | N/A | CNVS |
| FY2025 | $80M | N/A | 10.1% | N/A | CNVS |
| FY2026 | $70M | N/A | -23.1% | N/A | CNVS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CNVS
UNCLASSIFIED
Current IV
131.8%
IV Percentile
28th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact CNVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
BBLG
BREAKDOWN
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
ACCUMULATION
Exact BBLG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CNVS Moat Profile
Cyclical / Execution-Driven Positioning
Entertainment Operator
OpEx & R&D Reinvestment
54.7% of Rev ($54M)
90D Engineering Disclosures
0 Published
BBLG Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ CNVS vs BBLG Key Questions & Quantitative Answers
As of Nov 20, 2026, Cineverse Corp. (CNVS) is the stronger overall head-to-head candidate over Bone Biologics Corp (BBLG) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). CNVS carries a Unified Composite Score of 35.9/100 (SELL) at $1.73 (38.8x Forward P/E, -12.0% operating margin), whereas BBLG carries 44.8/100 (HOLD) at $0.27 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While BBLG currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. CNVS 35.9/100 SELL), CNVS captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-12.0% vs. 0.0% operating margin) and revenue trajectory (+110.0% vs. +0.0% YoY). Technical & Structure Timing Caution: CNVS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.9); meanwhile BBLG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CNVS leads the Growth & Scale pillar: CNVS posts +110.0% YoY revenue growth and +21.1% YoY earnings growth on $99M TTM revenue (42.7% gross margin, -12.0% operating margin), compared with BBLG at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), CNVS cumulative revenue shifted +40.0% while BBLG shifted +0.0%. In operating R&D and SG&A reinvestment, CNVS deploys 54.7% of Rev ($54M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BBLG.
CNVS screens cheaper on headline valuation multiples. CNVS trades at 38.8x Forward P/E, 38.8x Trailing P/E, 0.46x PEG, and 0.7x EV/Revenue (-17.9% FCF margin), whereas BBLG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CNVS (-4.6% ROE) versus BBLG (-47.5% ROE) capital efficiency.
In options market volatility and institutional positioning, CNVS carries 131.8% implied volatility (28th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 110% Vol realized risk). By comparison, BBLG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.97β · 102% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
BBLG vs CNVS · Reverse Pair
BBLG vs REVB
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal